Business Model & Revenue
PetMed Express, Inc. (NASDAQ: PETS) is a Delray Beach, FL-based online pet pharmacy operating 1800PetMeds.com. Founded in 1996, the company was a pioneer in online pet medication delivery but has lost market share to Chewy (founded 2011) and Amazon Pet.
Revenue streams: Prescription medications (highest margin), OTC pet medications, pet food and supplies, and auto-ship subscriptions.
Customer model: Direct-to-consumer online sales with veterinarian relationship management. The company serves pet owners directly and through veterinarian referrals.
Competitive position: Weak. Chewy dominates online pet retail with superior logistics, broader product selection, and aggressive marketing. Amazon Pet offers convenience and Prime shipping. PetMed Express has brand recognition and a long-standing customer base but no significant competitive advantages in logistics, pricing, or selection.
The company explored a sale (received buyout offers) but chose to remain public in June 2026. The decision to remain independent suggests either the offers were too low or management believes in the turnaround potential.
Financial Highlights
Income Statement
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | $179.02M | $226.97M | $274.12M | $247.57M |
| Revenue Growth | -21.1% | -17.2% | +10.7% | -9.1% |
| Gross Profit | $50.22M | $69.14M | $84.77M | $76.57M |
| Gross Margin | 28.1% | 30.5% | 30.9% | 30.9% |
| Operating Income | ($58.67)M | ($1.53)M | ($8.16)M | $6.05M |
| Net Income | ($~56)M | ($~2)M | ($~7)M | $5.5M |
Key Metrics
| Metric | Value |
|---|---|
| Market Cap (post-surge) | ~$50M |
| P/Sales (FY2026) | 0.28x |
| Cash | ~$50M+ |
| No Debt | Yes — debt-free |
| Enterprise Value | Near-zero or negative |
| Revenue Decline (2yr) | -35% |
The Revenue Decline
| Year | Revenue | Change |
|---|---|---|
| FY2022 | $272.3M | -10.3% |
| FY2023 | $247.6M | -9.1% |
| FY2024 | $274.1M | +10.7% |
| FY2025 | $227.0M | -17.2% |
| FY2026 | $179.0M | -21.1% |
| Peak to trough | $274M → $179M | -35% |
Valuation Context
At $50M market cap, PETS is cheap on every metric. But for a company with declining revenue, negative operating income, and no competitive advantage, cheap can get cheaper. The cash position (no debt) provides a floor, but ongoing losses will erode it. The major investor doubling down suggests the downside is limited, but the upside requires a real turnaround.
Competitive Landscape
The online pet pharmacy and supply market is dominated by a few large players:
- Chewy (CHWU): $4B+ revenue. Dominant online pet retailer. Superior logistics, broadest product selection, aggressive customer acquisition. Chewy's autoship program locks in recurring revenue.
- Amazon Pet: Leverages Amazon's logistics, Prime shipping, and pricing power. Growing share of online pet supply sales.
- Petco (WOOF): Omnichannel pet retailer with both physical stores and online. $6B+ revenue.
- PetSmart (private): Largest U.S. pet retailer with physical stores and growing online presence.
PetMed Express' position: The company pioneered online pet pharmacy but has been marginalized by larger competitors. Its advantages (brand longevity, direct relationships) are insufficient against Chewy's logistics and Amazon's reach. The company's decision to remain independent rather than accept a buyout is a bet on a turnaround that faces long odds.
Catalysts
-
Major investor doubles stake (June 9): A significant vote of confidence. Could signal activist involvement or strategic changes.
-
Revenue stabilization: First sequential Q4 increase since FY2024. If Q1 FY2027 shows continued stabilization, the turnaround thesis strengthens.
-
Prescription medication growth: Improving Rx sales (higher margin, recurring) could improve gross margins and revenue quality.
-
Auto-ship adoption: Subscription/auto-ship revenue provides recurring, predictable revenue.
-
Potential acquisition: Management received buyout offers. If a deal is eventually struck, it would provide a premium exit.
Reality: The investor doubling down is the most compelling signal, but one data point doesn't make a turnaround. The company needs to show sustained revenue growth and improving profitability to justify a higher valuation.
Key Risks
- Revenue collapsed 35% in two years ($274M → $179M). Three consecutive years of decline.
- ($58.7M) operating loss in FY2026, including substantial nonrecurring charges.
- Competing against Chewy ($4B+ revenue) and Amazon Pet with $50M market cap. Scale disadvantage is crushing.
- Goodwill impairment charges suggest the company overpaid for past acquisitions.
- No sustainable competitive advantage against Chewy's convenience or Amazon's pricing.
- Revenue may be stabilizing but hasn't demonstrated sustained growth yet.
- Buyout offers were received but management chose to remain public. Why did no deal close?
- Nano cap with limited liquidity and analyst coverage.
Our Thesis
PetMed Express is an online pet pharmacy that has been losing ground to Chewy and Amazon for years. The Q4 FY2026 earnings showed the first sequential Q4 revenue increase since FY2024 — a small positive data point in a long decline. But the annual numbers tell the real story:
Revenue: $274M (FY2024) → $227M (FY2025) → $179M (FY2026). Three consecutive years of double-digit revenue decline. The company has lost 35% of its revenue in two years. Operating income swung from $6M (FY2023) to ($58.7M) (FY2026). The FY2026 loss includes substantial nonrecurring charges, but even the underlying business is deeply unprofitable.
The bull case: A major investor doubled their stake on June 9, suggesting they see value at current levels. Management claims core operations are stabilizing. Prescription medication and auto-ship sales are improving. The company received buyout offers, implying someone sees strategic value. If the turnaround sticks and revenue stabilizes, the stock could re-rate significantly from its depressed levels.
The bear case: Chewy has $4B+ in revenue, Amazon Pet has unlimited marketing budget, and PetMed Express has no competitive advantage other than brand longevity. The pet pharmacy market is consolidating around a few dominant players, and PETS is not one of them. Revenue is still declining. The turnaround may be a dead cat bounce, not a recovery.
Neutral because the investor doubling down is interesting, but the business is still deteriorating. Wait for two consecutive quarters of revenue growth before getting constructive.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.